Top

Published in:

01-05-2014 | Letter to the Editors

MicroRNA-323-3p: a new biomarker and potential therapeutic target for rheumatoid arthritis

Authors: Tao Xu, Cheng Huang, Zhaolin Chen, Jun Li

Published in: Rheumatology International | Issue 5/2014

Abstract

Increased expression of microRNA-323-3p (miR-323-3p) has been demonstrated in rheumatoid arthritis synovial fibroblast. The gene encoding miR-323-3p, which is a biomarker in immune and inflammatory responses, occurs in an miRNA cluster in chromosomal region 14q32.31.

Duroux-Richard I, Jorgensen C, Apparailly F (2012) What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum 64(1):11–20. doi:10.1002/art.30651 PubMedCrossRef

Pandis I, Ospelt C, Karagianni N, Denis MC, Reczko M, Camps C, Hatzigeorgiou AG, Ragoussis J, Gay S, Kollias G (2012) Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model. Ann Rheum Dis 71(10):1716–1723. doi:10.1136/annrheumdis-2011-200803 PubMedCrossRef

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10(4):R101. doi:10.1186/ar2493 PubMedCentralPubMedCrossRef

de Rooy DP, Yeremenko NG, Wilson AG, Knevel R, Lindqvist E, Saxne T, Krabben A, Leijsma MK, Daha NA, Tsonaka S, Zhernakova A, Houwing-Duistermaat JJ, Huizinga TW, Toes RE, Baeten DL, Brouwer E, van der Helm-van Mil AH (2013) Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 72(5):769–775. doi:10.1136/annrheumdis-2012-202184 PubMedCrossRef

Walsh NC, Gravallese EM (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233(1):301–312. doi:10.1111/j.0105-2896.2009.00857.x PubMedCrossRef

Ammari M, Jorgensen C, Apparailly F (2013) Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Curr Opin Rheumatol 25(2):225–233. doi:10.1097/BOR.0b013e32835d8385 PubMedCrossRef

Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M (2011) The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 63(6):1582–1590. doi:10.1002/art.30321 PubMedCrossRef

Title: MicroRNA-323-3p: a new biomarker and potential therapeutic target for rheumatoid arthritis
Authors: Tao Xu
Cheng Huang
Zhaolin Chen
Jun Li
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 5/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-013-2767-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile

A randomized placebo-controlled clinical trial of phonophoresis for the treatment of chronic neck pain

Distribution of HLA-DRβ1 alleles among well-characterized rheumatoid arthritis patients from Western India

Efficacy and safety of oral low-dose glucocorticoids in patients with estrogen-dependent primary osteoarthritis

Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India

Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials